Stanford Researchers Develop 'Universal Vaccine' Spray to Combat Multiple Respiratory Illnesses
Summary
Stanford researchers have developed a nasal spray 'Universal Vaccine' that activates lung immune cells to provide broad protection against colds, flu, lung infections, and allergies, with potential lasting effects of about three months.
Key Points
- Stanford University researchers have developed a nasal spray 'Universal Vaccine' to protect against multiple respiratory illnesses and allergies.
- The vaccine activates lung macrophages to maintain an alert immune state, potentially preventing infections by 100 to 1000 times.
- Animal studies show the vaccine's effect lasts about three months, but human clinical trials are yet to begin.
- Experts see this as a breakthrough that could aid early pandemic response and seasonal respiratory infection prevention.
